

病態制御研究部門

Bioscience

病態生化学分野

Pathogenic Biochemistry

教授	濟木 育夫	Ikuo Saiki
准教授	早川 芳弘	Yoshihiro Hayakawa
助教	横山 悟	Satoru Yokoyama

◆ 著 書

- 1) Waiwut P, Inoue H, Saiki I, Sakurai H. Traditional Medicine: New Research. Motoo Y, editor. New York: Nova Science Publishers, Inc; 2013. Gomisin N: A herb-derived compound that enhances death receptor-mediated apoptosis of cancer cells; p. 147-57.

◆ 原 著

- 1) Jeong D, Watari K, Shirouzu T, Ono M, Koizumi K, Saiki I, Kim Y-C, Tanaka C, Higuchi R, Miyamoto T. Studies on lymphangiogenesis inhibitors from Korean and Japanese crude drugs. *Biol Pharm Bull.* 2013; 36(1): 152-7.
- 2) Kee J-Y*, Arita Y, Shinohara K, Ohashi Y, Sakurai H, Saiki I, Koizumi K. Anti-tumor immune activity by chemokine CX3CL1 in an orthotopic implantation of lung cancer model *in vivo*. *Mol Clin Oncol.* 2013; 1: 35-40.
- 3) Kee J-Y*, Itoh A, Hojo S, Hashimoto I, Igarashi Y, Tsukada K, Irimura T, Shibahara N, Nakayama T, Yoshie O, Sakurai H, Saiki I, Koizumi K. Chemokine CXCL16 suppresses liver metastasis of colorectal cancer via augmentation of tumor-infiltrating NKT cells in a murine model. *Oncol Rep.* 2013; 29(3): 975-82.
- 4) Xue R, Han N, Sakurai H, Saiki I, Ye C, Yin J. Cytotoxic cardiac glycosides from the roots of *Streptocaulon juvenas*. *Planta Medica.* 2013; 79(2): 157-62.
- 5) Abdelhamed S*, Yokoyama S, Hafiyani L, Kalauni SL, Hayakawa Y, Awale S, Saiki I. Identification of plant extracts sensitizing breast cancer cells to TRAIL. *Oncol Rep.* 2013; 29(5): 1991-8.
- 6) Haq R, Yokoyama S, Hawryluk EB, Jönsson GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R, Anderson DG, Garraway LA, Duncan LM, Morton DL, Hoon DS, Wargo JA, Song JS, Fisher DE. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. *Proc Natl Acad Sci USA.* 2013;110(11): 4321-6.
- 7) Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, Wargo JA, Song JS, Fisher DE, Arany Z, Widlund HR. Oncogenic BRAF regulates oxidative metabolism via PGC1 α and MITF. *Cancer Cell.* 2013; 23(3): 302-15.
- 8) Takahashi K, Takeda K, Saiki I, Irimura T, Hayakawa Y. Functional roles of TRAIL-DR5 interaction in B16F10 by activating NF- κ B pathway to induce metastatic potential. *Cancer Sci.* 2013; 104(5): 558-62.
Takahashi K, Takeda K, Saiki I, Irimura T, Hayakawa Y. RAIL-DR5 interaction by NF- κ B pathway induces metastatic potential. Lung metastasis of intravenously inoculated B16F10 mouse melanoma cells stimulated without (left panels) or with TRAIL (right panels) was visualized by bioluminescent imaging in mice. *Cancer Sci.* 2013; 104(5): Cover.
- 9) Lirdprapamongkol K, Sakurai H, Abdelhamed S, Yokoyama S, Athikomkulchai S, Viriyaroj A, Awale S, Ruchirawat S, Svasti J, Saiki I. Chrysin overcomes TRAIL resistance of cancer cells through Mcl-1 down-regulation by inhibiting STAT3 phosphorylation. *Int J Oncol.* 2013; 43(1): 329-37.
- 10) Refaat A, Abdelhamed S, Yagita H, Inoue H, Yokoyama S, Hayakawa Y, Saiki I. Berberine enhances TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis in breast cancer. *Oncol Letts.* 2013; 6(3): 840-4.
- 11) Shirouzu T, Watari K, Ono M, Koizumi K, Saiki I, Tanaka C, van Soest RW, Miyamoto T. Structure, synthesis, and biological activity of a C-20 bisacetylenic alcohol from a marine sponge *callyspongia* sp. *J Nat Prod.* 2013; 76(7): 1337-42.
- 12) Jiang Y-L, Miyanaga S, Han X-Z, Tang L-Q, Igarashi Y, Saiki I, Liu Z-P. Synthesis and structure-activity relationships studies of brartemicin analogues as anti-invasive agents. *J Antibiot.* 2013; 66(9): 531-7.
- 13) Sato K, Shin M-S, Sakimura A, Kwanishi M, Zhou Y, Tanaka T, Yokoyama S, Koizumi K, Saiki I, Sakurai H. Inverse correlatio

between threonine-669 phosphorylation and constitutive tyrosine phosphorylation in the asymmetric EGFR dimer conformation. *Cancer Sci.* 2013; 104(10): 1315-22.

- 14) Alves CP, Moraes MH, Sousa JF, Pontes CL, Ramão A, Yokoyama S, Trindade DM, Fisher DE, Espreafico EM. Myosin-Va contributes to manifestation of malignant-related properties in melanoma cells. *J Invest Dermatol.* 2013; 133(12): 2809-12.
- 15) Lirdprapamongkol K, Sakurai H, Abdelhamed S, Yokoyama S, Maruyama T, Athikomkulchai S, Viriyaroj A, Awale S, Yagita H, Ruchirawat S, Svasti J, Saiki I. A flavonoid chrysin suppresses hypoxic survival and metastatic growth of mouse breast cancer cells. *Oncol Rep.* 2013; 30(5): 2357-64.
- 16) Li P, Furusawa Y, Wei Z-L, Sakurai H, Tabuchi Y, Zhao Q-L, Saiki I, Kondo T. TAK1 promotes cell survival by TNFAIP3 and IL-8 dependent and NF- κ B independent pathway in HeLa cells exposed to heat stress. *Int J Hyperthermia.* 2013; 29(7): 688-95.
- 17) Bahar MA, Andoh T, Ogura K, Hayakawa Y, Saiki I, Kuraishi Y. Herbal medicine goshajinkigan prevents paclitaxel-induced mechanical allodynia without impairing anti-tumor activity of paclitaxel. *Evid Based Complement Alternat Med.* 2013; 2013: ID 849754.
- 18) Kin R, Kato S, Kaneto N, Sakurai H, Hayakawa Y, Li Feng, Tanaka K, Saiki I, Yokoyama S. Procyanidin C1 from *Cinnamomi* cortex inhibits TGF- β -induced epithelial- to-mesenchymal transition in A549 lung cancer cell lines. *Int J Oncol.* 2013; 43(6): 1901-6.
- 19) Li F, Tanaka K, Watanabe S, Tezuka Y, Saiki I. Dipasposide A, a novel pyridine alkaloid-coupled iridoid glucoside from the roots of *Dipsacus asper*. *Chem Pharm Bull.* 2013; 61(12): 1318-22.
- 20) Saiki I, Koizumi K, Goto H, Inujima A, Namiki T, Raimura M, Kogure T, Tatsumi T, Inoue H, Sakai S, Oka H, Fujimoto M, Hikiami H, Sakurai H, Shibahara N, Shimada Y, Origasa H. The long-term effects of a Kampo medicine, Juzentaihoto, on maintenance of antibody titer in elderly people after influenza vaccination. *Evid Based Complement Alternat Med.* 2013; 2013: ID 568074.
- 21) Hang PTN, Diep TT, Dong NT, Thanh PV, Saiki I. *Andrographis paniculata* (Burm.f) nees enhances cytotoxicity in combination with TRAIL and suppresses invasion and migration in MDA MB-231 cell line in vivo. *J Med Materials-Hanoi.* 2013; N6: 355-60.

◆ 総説

- 1) 済木育夫. トピックス: 第29回和漢医薬学会学術大会 シンポジウム1「和漢医薬学とがん」. *漢方医薬学雑誌.* 2013; 20(3): 15-7.
- 2) 小泉桂一, 犬島明子, 大江未来広, 柴原直利, 済木育夫. トピックス: 漢方薬のワクチンアジュバント効果. *最新医学.* 2013; 68(4): 133-7.
- 3) 済木育夫. 漢方薬とがん転移. *日本統合医療学会誌.* 2013; 6(1): 60-4.
- 4) 済木育夫. 漢方薬によるがん転移抑制とそのメカニズム. *日本女性医学学会ニュースレター.* 2013; 18(3): 5.
- 5) 横山 悟. 特集: 次世代シグナル伝達研究—先駆的基礎解析と臨床・創薬への展開—, 悪性黒色腫におけるシグナル伝達. *生化学.* 2013; 85(6): 469-74.
- 6) 早川芳弘. 特集: 腫瘍免疫学とがん免疫療法. 第1章 腫瘍免疫における免疫担当細胞と免疫分子の役割, 5 NK細胞およびNKT細胞の腫瘍免疫応答における役割. *実験医学.* 2013; 31(12増刊): 59-65.

◆ 学会報告

- 1) Saiki I. Curucumin and cancer metastasis. Hamdard International Unani Medicine Conference-2013; 2013 Feb 25-28; Pakistan. (Invited lecture)
- 2) Faisal SZ. *Helicobacter pylori* induces phosphorylation of epidermal growth factor receptor via p38/ERK activation in gastric epithelial cells in heparin binding-epidermal growth factor independent manner. Hamdard International Unani Medicine Conference-2013; 2013 Feb 25-28; Pakistan.
- 3) Habibie, Yokoyama S, Abdelhamed S, Awale S, Hayakawa Y, Saiki I. Resveratrol induces apoptosis in melanoma cells via downregulation of surviving expression. Second Makassar International Symposium on Pharmaceutical Science; 2013 Mar 21-22; Indonesia.
- 4) Saiki I. Curucumin and cancer metastasis. Second Makassar International Symposium on Pharmaceutical Science; 2013 Mar 21-22; Indonesia. (Invited lecture)
- 5) Faisal SZ, Refaat A, Saiki I, Sakurai I, Sugiyama T. *Helicobacter pylori* induces phosphorylation of epidermal growth factor

receptor via p38/ERK activation in gastric epithelial cells in heparin binding-epidermal growth factor independent manner. Digestive Disease Week 2013; 2013 May 18-21; Orlando.

- 6) Saiki I. Berberine and Cancer metastasis. "The advanced Research and Development of Chinese Medicine on Cancer" International Conference and Exhibition of the Modernization of Chinese Medicine and Health Products; 2013 Aug 15; Hong Kong. (Invited lecture)
- 7) Saiki I. Berberine and Cancer metastasis. International Seminar on Natural Product Discoveries and Its Impact on Pharmaceutical Sciences; 2013 Aug 20; Surabaya. (Invited lecture)
- 8) Managit C, Sakurai H, Saiki I. Enhancing effect of *Thevetia peruviana* flower extract on trail induced apoptosis in human cervical cancer cells. The 61st International Congress And Annual Meeting Of The Society For Medicinal Plant And Natural Product Research; 2013 Sep 1-5; Münster.
- 9) Saiki I, Habibie, Abdelhamed S, Awale S, Hayakawa Y, Yokoyama S. Resveratrol induces apoptosis in melanoma cells via downregulation of survivin expression. 8th World Congress on Advances in Oncology and 16th International Symposium on Molecular Medicine; 2013 Oct 10-12; Greece.
- 10) 高橋恵生, 永井 直, 済木育夫, 入村達郎, 早川芳弘. 生物発光イメージングによるマウス 4T1 細胞の腫瘍微小環境における転写因子 NF- κ B を介した炎症性シグナル活性化の時空間的解析. 第 17 回日本がん分子標的治療学会; 2013 Jun 12-13; 京都.
- 11) 早川芳弘. 生物発光イメージングによるがん病態における炎症性シグナルの時空間解析. ナノバイオ国際共同研究教育拠点 第 2 回若手国内シンポジウム NanoBio 第 6 回若手ネットワークワーキングシンポジウム; 2013 Jun 14-15; 富山. (招待講演)
- 12) 早川芳弘, 高橋恵生, 永井 直, 済木育夫, 入村達郎. 4T1 乳がんモデルにおける炎症性腫瘍微小環境形成における CD4⁺ T 細胞の重要性. 第 17 回日本がん免疫学会総会; 2013 Jul 3-5; 宇部.
- 13) 永井 直, 入村達郎, 早川芳弘. がん悪性化進展モデルにおける炎症性微小環境のがん悪性化形質獲得に与える影響. 第 22 回日本がん転移学会学術集会・総会; 2013 Jul 11-12; 松本.
- 14) 小泉桂一, 奇 知芸, 櫻井宏明, 入村達郎, 済木育夫. がん微小環境におけるケモカイン CXCL16 の二面性. がん免疫監視分子とがん細胞シグナル分子としての役割. 第 22 回日本がん転移学会学術集会; 2013 Jul 11-12; 松本.
- 15) 高橋恵生, 永井 直, 済木育夫, 入村達郎, 早川芳弘. マウス 4T1 乳がんモデルでの炎症性腫瘍微小環境形成における CD4 陽性 T 細胞の重要性. 第 22 回日本がん転移学会学術集会; 2013 Jul 11-12; 松本.
- 16) 金 諒英, 加藤真一郎, 兼頭直希, 櫻井宏明, 早川芳弘, 李 峰, 田中 謙, 済木育夫, 横山 悟. 桂皮由来の Procyanidin C1 による TGF- β 依存性上皮間葉転換を抑制する機能解析. 第 30 回和漢医薬学会総会; 2013 Aug 31-Sep 1; 金沢.
- 17) 堀江裕紀子, 田中 謙, 根本英幸, 小坂弘明, 小林 博, 済木育夫. 玄米酵素による機能性成分の生成に関する研究. 日本生薬学会第 60 回年会; 2013 Sep 7-8; 札幌.
- 18) Habibie, Abdelhamed S, Awale S, Hayakawa Y, Saiki I, Yokoyama S. Resveratrol induces apoptosis in melanoma cells via downregulation of survivin expression. The 72nd Annual Meeting of the Japanese Cancer Association; 2013 Oct 3-5; Yokohama.
- 19) Kaneto N, Kato S, Yokoyama S, Saiki I. RAC1 inhibitor suppresses gefitinib-resistant NSCLC cell migration. The 72nd Annual Meeting of the Japanese Cancer Association; 2013 Oct 3-5; Yokohama.
- 20) Kato S, Yokoyama S, Hayakawa Y, Saiki I. Mesenchymal-transitioned cancer cells instigate surrounding cancer cells to metastasis via secretion of WNT ligands. The 72nd Annual Meeting of the Japanese Cancer Association; 2013 Oct 3-5; Yokohama.
- 21) Abdelhamed S, Yokoyama S, Lia Hafiyani, Kalauni SK, Hayakawa Y, Awale S, Saiki I. Identification of plant extracts sensitizing breast cancer cells to TRAIL. The 72nd Annual Meeting of the Japanese Cancer Association; 2013 Oct 3-5; Yokohama.
- 22) Kimura Y, Sato-Matsushita M, Yoshimoto T, Tahara H, Saiki I, Irimura T, Hayakawa Y. Cross-talk between host and cancer cells amplify inflammation triggered by gdT17 cells to promote malignant progression. The 72nd Annual Meeting of the Japanese Cancer Association; 2013 Oct 3-5; Yokohama.
- 23) Nagai N, Saiki I, Irimura T, Hayakawa Y. Role of inflammatory microenvironment for acquiring malignant phenotypes in QR32 fibrosarcoma model. The 72nd Annual Meeting of the Japanese Cancer Association.; 2013 Oct 3-5; Yokohama.
- 24) Takahashi K, Nagai N, Tsuneyama K, Saiki I, Irimura T, Hayakawa Y. Requirement of CD4⁺ T cells for establishing inflammatory tumor microenvironment in 4T1 breast cancer model. The 72nd Annual Meeting of the Japanese Cancer

Association; 2013 Oct 3-5; Yokohama.

- 25) Hayakawa Y. Role of cross-talk between host immune responses and cancer cells in metastasis disease. 日本癌学会奨励賞受賞講演. The 72nd Annual Meeting of the Japanese Cancer Association; 2013 Oct 3-5; Yokohama. (招待講演)

◆ **その他**

- 1) 濟木育夫. 漢方薬によるがん転移の抑制とその作用機序. 臨床研修指導医のための漢方マスターズセミナー; 2013 Jan 19; 東京.
- 2) 濟木育夫. 第1回科学委員会医薬品専門部会. 独立行政法人医薬品医療機器総合機構 新薬審査第5部; 2013 Jul 9; 東京.
- 3) 濟木育夫. 第2回科学委員会医薬品専門部会. 独立行政法人医薬品医療機器総合機構 新薬審査第5部; 2013 Jul 9; 東京.
- 4) 田中 謙, 濟木育夫. 玄米発酵によるフェルラ酸類と 4-vinylguaiacol の生成. 第29回 FBRA 全国研究会; 2013 Aug 24-25; 札幌.
- 5) 横山 悟. コラボフェスタ 2013 「上皮間葉転換による薬剤耐性獲得機構を探る (ほくぎん若手研究者助成 成果報告); 2013 Sep 12; 富山.
- 6) 濟木育夫. 平成 25 年度 富山市民大学講座「生活医学薬学を学ぶ」漢方薬ちゃ, がんに効くがかね〜?; 2013 Sep 20; 富山.
- 7) 濟木育夫. 第3回医薬品専門部会. 独立行政法人医薬品医療機器総合機構 新薬審査第5部; 2013 Oct 29; 東京.